Daniel Castellano· @cdanicas · X·· 15 小时前评分70
正文 · 原文
🎯 #ESMO26 3º day Proffered paper GU non-prostate ca. Ph 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in mRCC.@montypal
👉 ORR 30%, CRS G3-4 6.0% with > ORR in> step-dose
@OncoAlert @myESMO @urotoday @DrYukselUrun @g_develasco @GuardConsortium @tompowles1
76 浏览 · 2 赞 · 2 转发 · 1 回复
帖内回复
- Daniel Castellano@cdanicas
🎯#ESMO26 Efficacy of AK112 (Ivonescimab), a PD-1/VEGF bispecific antibody, as 1L for first-line favorable-risk aRCC). @Jun Guo 👉 26 pts with ORR 65.2% only PR @OncoAlert @myESMO @urotoday @DrYukselUrun @GuardConsortium
来源：Daniel Castellano · x.com